Keywords: merck, co, s-p, shares, fall, vytorin, misses

Merck & Co and S-P shares fall as Vytorin misses primary endpoint in SEAS study

Article | 28 July 2008

Print This

There were sharp drops in the share prices of US drug majors Merck & Co and Schering-Plough after their controversial cholesterol ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in